| scholarly article | Q13442814 |
| review article | Q7318358 |
| P819 | ADS bibcode | 1997PNAS...94.5986G |
| P356 | DOI | 10.1073/PNAS.94.12.5986 |
| P8608 | Fatcat ID | release_vr7djj7boval7b3idt6ztdnbha |
| P932 | PMC publication ID | 33671 |
| P698 | PubMed publication ID | 9177153 |
| P5875 | ResearchGate publication ID | 14041943 |
| P2093 | author name string | C F Ware | |
| D R Green | |||
| P2860 | cites work | The fas antigen is involved in peripheral but not thymic deletion of T lymphocytes in T cell receptor transgenic mice | Q71678868 |
| Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape | Q71762882 | ||
| Antitumor effect of locally produced CD95 ligand | Q73034275 | ||
| Potential involvement of Fas and its ligand in the pathogenesis of Hashimoto's thyroiditis | Q73038929 | ||
| Crystal structure of the soluble human 55 kd TNF receptor-human TNF beta complex: implications for TNF receptor activation | Q27732032 | ||
| Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection | Q28237240 | ||
| Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family | Q28285445 | ||
| Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand | Q28513283 | ||
| Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis | Q30080034 | ||
| Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity | Q33488225 | ||
| Sertoli cell-enriched fractions in successful islet cell transplantation | Q34338335 | ||
| A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor | Q34661010 | ||
| Polymorphism of murine Fas ligand that affects the biological activity | Q36107352 | ||
| Transgenic expression of CD95 ligand on islet beta cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts. | Q36107808 | ||
| A new allele of the lpr locus, lprcg, that complements the gld gene in induction of lymphadenopathy in the mouse | Q36350481 | ||
| Cytotoxic T cells deficient in both functional fas ligand and perforin show residual cytolytic activity yet lose their capacity to induce lethal acute graft-versus-host disease | Q36366324 | ||
| The role of cell-mediated cytotoxicity in acute GVHD after MHC-matched allogeneic bone marrow transplantation in mice | Q36366817 | ||
| The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand | Q36367323 | ||
| Lethal effect of the anti-Fas antibody in mice | Q36696599 | ||
| CD95 ligand (FasL)-induced apoptosis is necessary for corneal allograft survival | Q37362984 | ||
| Fas and Fas ligand: lpr and gld mutations | Q40398275 | ||
| Human lung carcinomas express Fas ligand. | Q41120854 | ||
| Involvement of Fas ligand and Fas-mediated pathway in the cytotoxicity of human natural killer cells. | Q41165324 | ||
| Divergent induction of apoptosis and IL-8 secretion in HT-29 cells in response to TNF-alpha and ligation of Fas antigen | Q41277412 | ||
| Autocrine T-cell suicide mediated by APO-1/(Fas/CD95) | Q41371079 | ||
| Low dose streptozotocin-induced diabetes in mice: reduced IL-2 production and modulation of streptozotocin-induced hyperglycemia by IL-2 | Q41610648 | ||
| Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation. | Q42830166 | ||
| Fas ligand mediates activation-induced cell death in human T lymphocytes | Q42942730 | ||
| CD95-induced apoptosis of lymphocytes in an immune privileged site induces immunological tolerance | Q44051217 | ||
| Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas. | Q46925453 | ||
| Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome | Q55670225 | ||
| A role for CD95 ligand in preventing graft rejection | Q59066471 | ||
| Fas (CD95) participates in peripheral T cell deletion and associated apoptosis in vivo | Q63408405 | ||
| Fas Ligand-Induced Apoptosis as a Mechanism of Immune Privilege | Q63408406 | ||
| The structure of human lymphotoxin (tumor necrosis factor-beta) at 1.9-A resolution | Q67737964 | ||
| Fetal and postnatal testis shows immunoprivilege as donor tissue | Q68123624 | ||
| Prevention of the induction of allospecific cytotoxic T lymphocyte and delayed-type hypersensitivity responses by ultraviolet irradiation of corneal allografts | Q68879276 | ||
| Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice | Q71134585 | ||
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 5986-90 | |
| P577 | publication date | 1997-06-10 | |
| P1433 | published in | Proceedings of the National Academy of Sciences of the United States of America | Q1146531 |
| P1476 | title | Fas-ligand: privilege and peril | |
| P478 | volume | 94 |
| Q52992774 | A modification of the JAM test is necessary for a correct determination of apoptosis induced by FasL+ adherent tumor cells. |
| Q40903359 | A novel activation induced lymphocyte surface antigen, 90.12, is also expressed on apoptotic cells |
| Q41716419 | Activation and signal transduction via mitogen-activated protein (MAP) kinases in T lymphocytes |
| Q40874410 | Adenoviral vector which delivers FasL-GFP fusion protein regulated by the tet-inducible expression system |
| Q36641367 | Adenoviral-mediated gene transfer in lymphocytes. |
| Q33836347 | Apoptosis and CD95 ligand in immune privileged sites |
| Q34490923 | Apoptosis and the systolic dysfunction in congestive heart failure. Story of apoptosis interruptus and zombie myocytes |
| Q41698002 | Apoptosis in liver transplantation: a mechanism contributing to immune modulation, preservation injury, neoplasia, and viral disease |
| Q34395580 | Apoptosis regulators and their role in tumorigenesis |
| Q37902996 | Apoptosis: why and how does it occur in biology? |
| Q33782516 | Application of a Fas ligand encoding a recombinant adenovirus vector for prolongation of transgene expression |
| Q90399249 | CD146 T cells in lung cancer: its function, detection, and clinical implications as a biomarker and therapeutic target |
| Q38868176 | CD95 is required for the early control of parasite burden in the liver of Leishmania donovani-infected mice. |
| Q41964046 | CD95 ligand (CD95L) in normal human lymphoid tissues: a subset of plasma cells are prominent producers of CD95L. |
| Q73407777 | Cancer vaccines |
| Q33840464 | Cloak and dagger in the avoidance of immune surveillance |
| Q40966405 | Construction of a recombinant adenovirus vector encoding Fas ligand with a CRE/Loxp inducible system |
| Q34593940 | Cytokines for surgeons |
| Q41745119 | Deciphering the apoptotic pathway: all roads lead to death |
| Q40793025 | Down-regulation of human alloimmune responses by genetically engineered expression of CD95 ligand on stimulatory and target cells |
| Q45867755 | Effective repeat administration with adenovirus vectors to the muscle |
| Q77758162 | Endothelial expression of Fas ligand in transgenic rats under the temporal control of a tetracycline-inducible system |
| Q34059300 | Eosinophil apoptosis--pathophysiologic and therapeutic implications. |
| Q33860215 | Fas and Fas ligand in gut and liver |
| Q41724564 | Fas and Fas-ligand expression in human pancreatic cancer. |
| Q41010578 | Functional significance of adhesion molecules in Fas-dependent apoptotic cell death induced by interleukin-2-activated T cells |
| Q41014732 | Involvement of NF-AT in type I human T-cell leukemia virus Tax-mediated Fas ligand promoter transactivation |
| Q28371622 | Microtubule dysfunction induced by paclitaxel initiates apoptosis through both c-Jun N-terminal kinase (JNK)-dependent and -independent pathways in ovarian cancer cells |
| Q40633735 | Modification of tumor cells with Fas (CD95) antigen gene and Fas ligand (CD95L) gene transfection by electroporation for immunotherapy of cancer |
| Q78693607 | Murine heart transgenic Fas ligand expression protects against allograft rejection |
| Q40866394 | Non-thermal effects of continuous 2.45 GHz microwaves on Fas-induced apoptosis in human Jurkat T-cell line |
| Q37168735 | Origin, regulation and physiological function of intestinal oeosinophils |
| Q77173735 | Pathogenesis of mousepox in H-2(d) mice: evidence for MHC class I-restricted CD8(+) and MHC class II-restricted CD4(+) CTL antiviral activity in the lymph nodes, spleen and skin, but not in the conjunctivae |
| Q40639880 | Perillyl alcohol as a radio-/chemosensitizer in malignant glioma |
| Q40812934 | Pro-apoptotic and anti-apoptotic effects of transferrin and transferrin-derived glycans on hematopoietic cells and lymphocytes |
| Q37194997 | Proinflammatory consequences of transgenic fas ligand expression in the heart |
| Q34091319 | Protein kinase Ctheta: a new essential superstar on the T-cell stage |
| Q33636576 | Reflections on tolerance, self-tolerance and Felix Milgrom |
| Q73965629 | Regeneration and tolerance factor is expressed during T-lymphocyte activation and plays a role in apoptosis |
| Q40841750 | Regeneration and tolerance factor's potential role in T-cell activation and apoptosis |
| Q73169381 | Regulation of fas ligand expression in breast cancer cells by estrogen: functional differences between estradiol and tamoxifen |
| Q74070693 | Regulation of mast cell survival by IgE |
| Q35596728 | Repeated adenoviral administration into the biliary tract can induce repeated expression of the original gene construct in rat livers without immunosuppressive strategies |
| Q34319309 | Review article: a conceptual approach to understanding the molecular mechanisms of cancer development in Barrett's oesophagus |
| Q35077041 | Stressed to death: implication of lymphocyte apoptosis for psychoneuroimmunology |
| Q77892082 | Susceptibility to lupus nephritis in the NZB/W model system |
| Q33898966 | T cell life and death signalling via TNF-receptor family members |
| Q77383438 | Targeting the function of mature dendritic cells by human cytomegalovirus: a multilayered viral defense strategy |
| Q33542332 | The Fas counterattack: cancer as a site of immune privilege |
| Q57821796 | The Fate of Allogeneic Pancreatic Islets following Intraportal Transplantation: Challenges and Solutions |
| Q57201553 | Transplantation of cells and tissues expressing Fas ligand |
| Q77769105 | Tumor immunology: the glass is half full |
| Q54766634 | Xenotransplantaion of islet from fas ligand transgenic mice in experimental diabetic rat. |
Search more.